• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MDR
Click for more information
3.45% 30.0¢

MEDADVISOR LIMITED - Announcements

Market Cap $215.0M  ! watchlist Created with Sketch. Add to my watchlist

MedAdvisor Limited is an Australia-based company that is engaged in digital medication... MedAdvisor Limited is an Australia-based company that is engaged in digital medication adherence solutions. The Company's segments include Australia, the United States, the United Kingdom and Asia Operations. The Company's products suite includes Medication Management Application, PlusOne Pharmacy Software and Pharma Patient Experience Platform. The Medication Management Application connects to the pharmacy from the mobile phone. The Company's subsidiaries include MedAdvisor International Pty. Ltd., Health Enterprises 2 Pty. Ltd., MedAdvisor Welam UK Ltd., MedAdvisor Welam USA Inc. and Adheris, LLC.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
MDR Supplement to Investor Presentation - March 2019PRICE SENSITIVE22/03/19
MDR MedAdvisor Announces Agreement with Adheris Health SAPRICE SENSITIVE22/03/19
MDR Trading HaltPRICE SENSITIVE20/03/19
MDR Trading HaltPRICE SENSITIVE20/03/19
MDR MDR Investor Presentation - Mar-1918/03/19
MDR MDR H1 FY2019 Financial Report & Appendix 4DPRICE SENSITIVE25/02/19
MDR MedAdvisor Executive Team Changes12/02/19
MDR Lapsing of Read Rights08/02/19
MDR Appendix 3b Exercise of Options08/02/19
MDR MedAdvisor Quarterly Report & Appendix 4CPRICE SENSITIVE31/01/19
MDR Appendix 3B Amendment11/01/19
MDR Appendix 3B - Issue of Employee Incentive Options11/01/19
MDR Exercise of Lead Manager Options13/12/18
MDR MedAdvisor Partners with Thrivor to support PatientsPRICE SENSITIVE06/12/18
MDR MedAdvisor to launch in Asia with Zuellig PharmaPRICE SENSITIVE03/12/18
MDR PEP and International UpdatePRICE SENSITIVE26/11/18
MDR Appendix 3Y Director's Interest Notice12/11/18
MDR Appendix 3B Issue subsequent to Exercise of Options12/11/18
MDR Performance Shares, Options and Release of Securities12/11/18
MDR MedAdvisor Quarterly Report & Appendix 4CPRICE SENSITIVE26/10/18
MDR 2018 AGM Investor Presentation23/10/18
MDR 2018 AGM Results & Chairman's Address23/10/18
MDR Release from Escrow of Healthnotes Consideration Shares17/10/18
MDR MedAdvisor Makes Strategic Appointments for US Expansion10/10/18
MDR Notice of Annual General Meeting - 201804/10/18
MDR Appendix 3B Issue of Employee Incentive Options01/10/18
MDR FY18 Results Investor Presentation19/09/18
MDR MedAdvisor Expands Revenue Streams in Clinical TrialsPRICE SENSITIVE10/09/18
MDR MedAdvisor FY18 Annual Report & Appendix 4EPRICE SENSITIVE31/08/18
MDR MedAdvisor Corporate Governance Statement 201831/08/18
MDR MedAdvisor Appendix 4G 30 June 1831/08/18
MDR Ceasing to be a substantial holder from MUFG31/08/18
MDR Ceasing to be a substantial holder from MS30/08/18
MDR MedAdvisor and HPS Announce Integrated Medication SolutionPRICE SENSITIVE30/08/18
MDR Appendix 3B Issue and Exercise of Employee Options24/08/18
MDR Vesting of CEO Performance Rights24/08/18
MDR Becoming a substantial holder from MUFG24/08/18
MDR Becoming a substantial holder from MS23/08/18
MDR MedAdvisor Quarterly Report & Appendix 4CPRICE SENSITIVE25/07/18
MDR Co-Marketing & Licence Agreement with US Dispense Vendor PDXPRICE SENSITIVE20/06/18
MDR MDR Signs Agreement with EBOS Subsidiary ZESTPRICE SENSITIVE15/06/18
MDR MDR Release from Escrow and Appendix 3B31/05/18
MDR Release of securities from voluntary escrow17/05/18
MDR MedAdvisor to Launch Customised TerryWhite Chemmart AppPRICE SENSITIVE03/05/18
MDR MDR March 2018 Quarterly Report & Appendix 4CPRICE SENSITIVE30/04/18
MDR Appendix 3B - Issue and Exercise of Options16/04/18
MDR Corporate Governance Statement - 201713/04/18
MDR MedAdvisor Reaches 1 Million Connected Patients06/04/18
MDR MDR H1 FY2018 Financial Report & Appendix 4DPRICE SENSITIVE26/02/18
MDR MDR December 2017 Quarterly Report & Appendix 4CPRICE SENSITIVE25/01/18
MDR Appendix 3B - Issue of Employee Options02/01/18
MDR MDR - Release of Securities from Escrow16/11/17
MDR Appendix 3B - Issue of Employee Incentive Options14/11/17
MDR MDR Cleansing Notice - EBOS Placement30/10/17
MDR Becoming a substantial holder25/10/17
MDR EBO: EBOS investment in MedAdvisor24/10/17
MDR 2017 AGM Results & Chairman's Address24/10/17
MDR MDR AGM Investor Presentation24/10/17
MDR Appendix 3B - EBOS Placement24/10/17
MDR MedAdvisor $9.5m Investment from EBOSPRICE SENSITIVE24/10/17
MDR Trading HaltPRICE SENSITIVE20/10/17
MDR Appendix 3Y Change in Directors Interest - Xenos19/10/17
MDR Appendix 3Y Change in Directors Interest - Swinnerton19/10/17
MDR Appendix 3Y Change in Directors Interest - Read19/10/17
MDR MDR September 2017 Quarterly Report & Appendix 4CPRICE SENSITIVE19/10/17
MDR Appendix 3B - New Share Issue19/10/17
MDR Appendix 3B - Founder Performance Shares and Read Rights19/10/17
MDR Notice of Annual General Meeting11/10/17
MDR MDR Investor Presentation - September 201713/09/17
MDR MedAdvisor to Advance Global Expansion Strategy12/09/17
MDR MDR Appendix 4G Key Corporate Governance Disclosures30/08/17
MDR ASX Listing Rule 4.10.19 Statement30/08/17
MDR MDR Final FY17 Results & Appendix 4EPRICE SENSITIVE30/08/17
MDR MDR Jun-17 Quarterly Report & 4CPRICE SENSITIVE17/07/17
MDR Appendix 3Y28/06/17
MDR MedAdvisor Appoints Chief Technology Officer13/06/17
MDR MedAdvisor Partners with Discount Drug StoresPRICE SENSITIVE31/05/17
MDR MedAdvisor Partners with US Company iHealth LabsPRICE SENSITIVE29/05/17
MDR Appendix 3B24/05/17
MDR MDR Mar-17 Quarterly Report and 4CPRICE SENSITIVE11/04/17
MDR Investor Presentation - March 201720/03/17
MDR Change in Director's Interest Notice - Xenos16/03/17
MDR Change in Director's Interest Notice - Bennetto16/03/17
MDR Vesting of CEO Performance Rights06/03/17
MDR Change of Director's Interest Notice28/02/17
MDR Change of Director's Interest Notice27/02/17
MDR MDR - Wholesale investor presentation - Sydney 21 Feb 201721/02/17
MDR Completion of OzDocsOnline Acquisition by MedAdvisor20/02/17
MDR MedAdvisor Appendix 4D and Financial Report - Dec16PRICE SENSITIVE17/02/17
MDR MedAdvisor launches Pharmacy Software to Improve Services03/02/17
MDR Quarterly Activities Report and Appendix 4CPRICE SENSITIVE16/01/17
MDR MedAdvisor Acquires OzDocsOnlinePRICE SENSITIVE10/01/17
MDR Vesting of Performance Rights03/01/17
MDR Appendix 3B - Issue of Options16/12/16
MDR Rapid Growth of Patient Engagement ProgramsPRICE SENSITIVE12/12/16
MDR MedAdvisor Signs Pfizer for Patient Engagement ProgramPRICE SENSITIVE08/12/16
MDR MedAdvisor Partners with Asthma AustraliaPRICE SENSITIVE29/11/16
MDR Quotation of Shares Released from Escrow14/11/16
MDR Release of Restricted Shares from Escrow-MDR.AX 01/11/16
MDR Appendix 3B - Consideration Shares-MDR.AX 31/10/16
MDR Supplement to Investor Presentation - March 2019
22/03/19PRICE SENSITIVE
MDR MedAdvisor Announces Agreement with Adheris Health SA
22/03/19PRICE SENSITIVE
MDR Trading Halt
20/03/19PRICE SENSITIVE
MDR Trading Halt
20/03/19PRICE SENSITIVE
MDR MDR Investor Presentation - Mar-19
18/03/19
MDR MDR H1 FY2019 Financial Report & Appendix 4D
25/02/19PRICE SENSITIVE
MDR MedAdvisor Executive Team Changes
12/02/19
MDR Lapsing of Read Rights
08/02/19
MDR Appendix 3b Exercise of Options
08/02/19
MDR MedAdvisor Quarterly Report & Appendix 4C
31/01/19PRICE SENSITIVE
MDR Appendix 3B Amendment
11/01/19
MDR Appendix 3B - Issue of Employee Incentive Options
11/01/19
MDR Exercise of Lead Manager Options
13/12/18
MDR MedAdvisor Partners with Thrivor to support Patients
06/12/18PRICE SENSITIVE
MDR MedAdvisor to launch in Asia with Zuellig Pharma
03/12/18PRICE SENSITIVE
MDR PEP and International Update
26/11/18PRICE SENSITIVE
MDR Appendix 3Y Director's Interest Notice
12/11/18
MDR Appendix 3B Issue subsequent to Exercise of Options
12/11/18
MDR Performance Shares, Options and Release of Securities
12/11/18
MDR MedAdvisor Quarterly Report & Appendix 4C
26/10/18PRICE SENSITIVE
MDR 2018 AGM Investor Presentation
23/10/18
MDR 2018 AGM Results & Chairman's Address
23/10/18
MDR Release from Escrow of Healthnotes Consideration Shares
17/10/18
MDR MedAdvisor Makes Strategic Appointments for US Expansion
10/10/18
MDR Notice of Annual General Meeting - 2018
04/10/18
MDR Appendix 3B Issue of Employee Incentive Options
01/10/18
MDR FY18 Results Investor Presentation
19/09/18
MDR MedAdvisor Expands Revenue Streams in Clinical Trials
10/09/18PRICE SENSITIVE
MDR MedAdvisor FY18 Annual Report & Appendix 4E
31/08/18PRICE SENSITIVE
MDR MedAdvisor Corporate Governance Statement 2018
31/08/18
MDR MedAdvisor Appendix 4G 30 June 18
31/08/18
MDR Ceasing to be a substantial holder from MUFG
31/08/18
MDR Ceasing to be a substantial holder from MS
30/08/18
MDR MedAdvisor and HPS Announce Integrated Medication Solution
30/08/18PRICE SENSITIVE
MDR Appendix 3B Issue and Exercise of Employee Options
24/08/18
MDR Vesting of CEO Performance Rights
24/08/18
MDR Becoming a substantial holder from MUFG
24/08/18
MDR Becoming a substantial holder from MS
23/08/18
MDR MedAdvisor Quarterly Report & Appendix 4C
25/07/18PRICE SENSITIVE
MDR Co-Marketing & Licence Agreement with US Dispense Vendor PDX
20/06/18PRICE SENSITIVE
MDR MDR Signs Agreement with EBOS Subsidiary ZEST
15/06/18PRICE SENSITIVE
MDR MDR Release from Escrow and Appendix 3B
31/05/18
MDR Release of securities from voluntary escrow
17/05/18
MDR MedAdvisor to Launch Customised TerryWhite Chemmart App
03/05/18PRICE SENSITIVE
MDR MDR March 2018 Quarterly Report & Appendix 4C
30/04/18PRICE SENSITIVE
MDR Appendix 3B - Issue and Exercise of Options
16/04/18
MDR Corporate Governance Statement - 2017
13/04/18
MDR MedAdvisor Reaches 1 Million Connected Patients
06/04/18
MDR MDR H1 FY2018 Financial Report & Appendix 4D
26/02/18PRICE SENSITIVE
MDR MDR December 2017 Quarterly Report & Appendix 4C
25/01/18PRICE SENSITIVE
MDR Appendix 3B - Issue of Employee Options
02/01/18
MDR MDR - Release of Securities from Escrow
16/11/17
MDR Appendix 3B - Issue of Employee Incentive Options
14/11/17
MDR MDR Cleansing Notice - EBOS Placement
30/10/17
MDR Becoming a substantial holder
25/10/17
MDR EBO: EBOS investment in MedAdvisor
24/10/17
MDR 2017 AGM Results & Chairman's Address
24/10/17
MDR MDR AGM Investor Presentation
24/10/17
MDR Appendix 3B - EBOS Placement
24/10/17
MDR MedAdvisor $9.5m Investment from EBOS
24/10/17PRICE SENSITIVE
MDR Trading Halt
20/10/17PRICE SENSITIVE
MDR Appendix 3Y Change in Directors Interest - Xenos
19/10/17
MDR Appendix 3Y Change in Directors Interest - Swinnerton
19/10/17
MDR Appendix 3Y Change in Directors Interest - Read
19/10/17
MDR MDR September 2017 Quarterly Report & Appendix 4C
19/10/17PRICE SENSITIVE
MDR Appendix 3B - New Share Issue
19/10/17
MDR Appendix 3B - Founder Performance Shares and Read Rights
19/10/17
MDR Notice of Annual General Meeting
11/10/17
MDR MDR Investor Presentation - September 2017
13/09/17
MDR MedAdvisor to Advance Global Expansion Strategy
12/09/17
MDR MDR Appendix 4G Key Corporate Governance Disclosures
30/08/17
MDR ASX Listing Rule 4.10.19 Statement
30/08/17
MDR MDR Final FY17 Results & Appendix 4E
30/08/17PRICE SENSITIVE
MDR MDR Jun-17 Quarterly Report & 4C
17/07/17PRICE SENSITIVE
MDR Appendix 3Y
28/06/17
MDR MedAdvisor Appoints Chief Technology Officer
13/06/17
MDR MedAdvisor Partners with Discount Drug Stores
31/05/17PRICE SENSITIVE
MDR MedAdvisor Partners with US Company iHealth Labs
29/05/17PRICE SENSITIVE
MDR Appendix 3B
24/05/17
MDR MDR Mar-17 Quarterly Report and 4C
11/04/17PRICE SENSITIVE
MDR Investor Presentation - March 2017
20/03/17
MDR Change in Director's Interest Notice - Xenos
16/03/17
MDR Change in Director's Interest Notice - Bennetto
16/03/17
MDR Vesting of CEO Performance Rights
06/03/17
MDR Change of Director's Interest Notice
28/02/17
MDR Change of Director's Interest Notice
27/02/17
MDR MDR - Wholesale investor presentation - Sydney 21 Feb 2017
21/02/17
MDR Completion of OzDocsOnline Acquisition by MedAdvisor
20/02/17
MDR MedAdvisor Appendix 4D and Financial Report - Dec16
17/02/17PRICE SENSITIVE
MDR MedAdvisor launches Pharmacy Software to Improve Services
03/02/17
MDR Quarterly Activities Report and Appendix 4C
16/01/17PRICE SENSITIVE
MDR MedAdvisor Acquires OzDocsOnline
10/01/17PRICE SENSITIVE
MDR Vesting of Performance Rights
03/01/17
MDR Appendix 3B - Issue of Options
16/12/16
MDR Rapid Growth of Patient Engagement Programs
12/12/16PRICE SENSITIVE
MDR MedAdvisor Signs Pfizer for Patient Engagement Program
08/12/16PRICE SENSITIVE
MDR MedAdvisor Partners with Asthma Australia
29/11/16PRICE SENSITIVE
MDR Quotation of Shares Released from Escrow
14/11/16
MDR Release of Restricted Shares from Escrow-MDR.AX
01/11/16
MDR Appendix 3B - Consideration Shares-MDR.AX
31/10/16
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
30.0¢ 		Change
0.010(3.45%) 		Mkt cap ! $215.0M
Open High Low Value Volume
29.0¢ 30.0¢ 27.5¢ $254.8K 889.6K

Buyers (Bids)

No. Vol. Price($)
2 39326 30.0¢
 

Sellers (Offers)

Price($) Vol. No.
30.5¢ 2917 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
Last
29.0¢ 		  Change
0.010 ( 1.75 %)
Open High Low Volume
28.0¢ 29.0¢ 27.5¢ 86353
Last updated 15.19pm 15/11/2024 ?
MDR (ASX) Chart

Top Stories

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Banshee's historic trenches prove rich in antimony and gold for GDM Great Divide Mining Ltd has found high-grade antimony and gold through geochemical sampling at its Banshee prospect in Queensland
Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.